April 2-3, 2027 - Ritz-Carlton - Rancho Mirage, California
This course offers Live (in-person) and Livestream (virtual) attendance options
Discover how emerging science is reshaping GI cancer care. Expert faculty will highlight breakthroughs in targeted therapy, immunotherapy, radiopharmaceuticals, molecular profiling, transplant strategies, and precision oncology across pancreatic, hepatobiliary, gastroesophageal, neuroendocrine, and colorectal cancers.
Expert faculty will examine innovative approaches to precision oncology, including next-generation radionuclide therapies for neuroendocrine tumors, the expanding role of RAS inhibition and molecularly targeted treatments in pancreatic cancer, and strategies for integrating biomarker-driven therapies earlier in the disease course. Participants will explore contemporary management of hepatocellular carcinoma, including transplant candidacy, downstaging approaches, perioperative treatment considerations, and the integration of systemic and locoregional therapies.
Additional sessions will address advances in biliary tract cancers, including FGFR2-targeted therapies and perioperative management, as well as emerging therapeutic targets in gastric and esophageal cancers such as HER2, CLDN18.2, and immunotherapy-based approaches. The activity will also highlight the growing clinical relevance of tumor spatial architecture, organ preservation strategies, measurable residual disease (MRD), and molecular characterization in treatment selection.
.